4SC strengthens patent protection for its epigenetic cancer drug in China

17-Aug-2015 - 4SC AG announced that it has further strengthened the patent protection for its epigenetic anti-cancer compound 4SC-202 - a selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China. The Chinese Intellectual Property Office (SIPO) has granted a patent relating to the tosylate salt of the ...

4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases

27-Feb-2013 - 4SC AG announced that its fully-owned research subsidiary 4SC Discovery GmbH has entered into an exclusive research and license agreement with LEO Pharma A/S, Ballerup, Denmark with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin ...

4SC Discovery and CRELUX enter into strategic alliance

20-Apr-2012 - The biotech company 4SC AG announced that its drug discovery affiliate 4SC Discovery GmbH and CRELUX GmbH have entered into a strategic partnership for integrated drug discovery services. Both partners are adding core competencies to a joint discovery platform geared towards comprehensive drug ...

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

20-Apr-2011 - 4SC AG and Yakult Honsha Co.; Ltd. announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialization of resminostat in Japan. Resminostat, an oral, pan-histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by 4SC in ...

4SC Awarded First Place and International Platinum Award for its 2009 Annual Report in the Biotech Category

19-Jul-2010 - 4SC AG won first place and the platinum award, the highest level award, from the League of American Communications Professionals (LACP) for its annual report 2009 in the biotech category. The jury of the LACP, based in San Diego, USA, appraised over 4,000 international annual reports this year ...

4SC Announces Treatment of First Patient in a Phase I Study of 4SC-205

Oral Eg5 kinesin spindle protein inhibitor to be evaluated in solid tumour and malignant lymphoma patients

16-Feb-2010 - 4SC AG announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas. This first-in-man Phase I, open label, dose escalation trial, the “AEGIS” study, in patients to investigate the ...

4SC Announces Clinical Advancements in its Oncology Pipeline

23-Dec-2009 - 4SC AG announced progress in the initiation of three new clinical trials for its oncology franchise: - Initiation of a Phase II trial with the oral, pan histone deacetylase (HDAC) inhibitor resminostat (4SC-201) for the treatment of relapsed or refractory Hodgkin’s Lymphoma (HL) - First-in-man ...